Jove
Visualize
Contact Us

Related Concept Videos

Embryonic Stem Cells00:57

Embryonic Stem Cells

4.7K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
4.7K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.1K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.1K
Stem Cell Culture01:17

Stem Cell Culture

6.0K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
6.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

910
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
910
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.

Stem cell reports·2026
Same author

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

Stem cell reports·2026
Same author

Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.

Stem cell reports·2025
Same author

The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

Stem cell reports·2018
Same author

Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling.

Stem cells (Dayton, Ohio)·2017
Same author

Regulatory considerations for pluripotent stem cell therapies.

Progress in brain research·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 19, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K

2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.

Larry A Couture1, Melissa K Carpenter2

  • 1Beckman Research Institute, City of Hope, Duarte, California, USA; lcouture@coh.org melissa@carpentergroupstrategy.com.

Stem Cells Translational Medicine
|August 20, 2015
PubMed
Summary

Regulatory hurdles for human embryonic stem cell (hESC) therapies create redundant testing and uncertainty. A proposed solution aims to streamline FDA regulations for hESC-derived products, encouraging investment in these promising treatments.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.8K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.9K

Related Experiment Videos

Last Updated: Jan 19, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.8K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.9K

Area of Science:

  • Biomedical Science
  • Regulatory Science
  • Cell Therapy

Background:

  • Human embryonic stem cell (hESC)-derived therapeutics are advancing into clinical trials.
  • Current U.S. Food and Drug Administration (FDA) regulations for hESCs, established before their discovery and unrevised since 2005, pose challenges.
  • hESCs are regulated as human tissue and biologics, leading to overlapping and redundant testing requirements.

Purpose of the Study:

  • To identify and address regulatory ambiguities in hESC donor eligibility and testing.
  • To propose a solution that resolves regulatory uncertainty and risk for hESC-derived cell therapies.
  • To encourage investment in the development of hESC-based therapeutics by simplifying the regulatory landscape.

Main Methods:

  • Analysis of current FDA regulations pertaining to human tissue and biologic agents.
  • Identification of redundant testing requirements for hESC-derived products.
  • Formulation of a proposed regulatory solution for FDA consideration.

Main Results:

  • Existing regulations impose redundant donor and product testing on hESC-derived therapeutics.
  • Ambiguity exists regarding the application of regulations to hESC lines established before 2005.
  • Current regulatory practices create a burdensome environment, deterring developer investment.

Conclusions:

  • Regulatory ambiguity and redundant testing requirements for human embryonic stem cell lines, especially pre-2005 lines, concern drug developers.
  • Many hESC lines technically fail to meet FDA eligibility rules for product licensure.
  • A proposed solution aims to resolve these issues, fostering discussion among stakeholders and the FDA.